Microarray Based Diagnosis Profits from Better Documentation of Gene Expression Signatures

Overview

Journal PLoS Comput Biol

Specialty Biology

Date 2008 Feb 20

PMID 18282081

Citations 13

Authors

Dennis Kostka

Rainer Spang

Affiliations

Soon will be listed here.

Abstract

Microarray gene expression signatures hold great promise to improve diagnosis and prognosis of disease. However, current documentation standards of such signatures do not allow for an unambiguous application to study-external patients. This hinders independent evaluation, effectively delaying the use of signatures in clinical practice. Data from eight publicly available clinical microarray studies were analyzed and the consistency of study-internal with study-external diagnoses was evaluated. Study-external classifications were based on documented information only. Documenting a signature is conceptually different from reporting a list of genes. We show that even the exact quantitative specification of a classification rule alone does not define a signature unambiguously. We found that discrepancy between study-internal and study-external diagnoses can be as frequent as 30% (worst case) and 18% (median). By using the proposed documentation by value strategy, which documents quantitative preprocessing information, the median discrepancy was reduced to 1%. The process of evaluating microarray gene expression diagnostic signatures and bringing them to clinical practice can be substantially improved and made more reliable by better documentation of the signatures.

Citing Articles

Profound impact of sample processing delay on gene expression of multiple myeloma plasma cells.

Meissner T, Seckinger A, Hemminki K, Bertsch U, Foersti A, Haenel M BMC Med Genomics. 2015; 8:85.

PMID: 26714877 PMC: 4696100. DOI: 10.1186/s12920-015-0161-6.

A measure of the impact of CV incompleteness on prediction error estimation with application to PCA and normalization.

Hornung R, Bernau C, Truntzer C, Wilson R, Stadler T, Boulesteix A BMC Med Res Methodol. 2015; 15:95.

PMID: 26537575 PMC: 4634762. DOI: 10.1186/s12874-015-0088-9.

miRNAs in multiple myeloma--a survival relevant complex regulator of gene expression.

Seckinger A, Meissner T, Moreaux J, Benes V, Hillengass J, Castoldi M Oncotarget. 2015; 6(36):39165-83.

PMID: 26472281 PMC: 4770764. DOI: 10.18632/oncotarget.5381.

OncoRep: an n-of-1 reporting tool to support genome-guided treatment for breast cancer patients using RNA-sequencing.

Meissner T, Fisch K, Gioia L, Su A BMC Med Genomics. 2015; 8:24.

PMID: 25989980 PMC: 4494802. DOI: 10.1186/s12920-015-0095-z.

Massive transcriptional perturbation in subgroups of diffuse large B-cell lymphomas.

Rosolowski M, Lauter J, Abramov D, Drexler H, Hummel M, Klapper W PLoS One. 2013; 8(11):e76287.

PMID: 24223701 PMC: 3817189. DOI: 10.1371/journal.pone.0076287.

References

Bhattacharjee A, Richards W, Staunton J, Li C, Monti S, Vasa P . Classification of human lung carcinomas by mRNA expression profiling reveals distinct adenocarcinoma subclasses. Proc Natl Acad Sci U S A. 2001; 98(24):13790-5. PMC: 61120. DOI: 10.1073/pnas.191502998. View

Irizarry R, Wu Z, Jaffee H . Comparison of Affymetrix GeneChip expression measures. Bioinformatics. 2006; 22(7):789-94. DOI: 10.1093/bioinformatics/btk046. View

Tibshirani R, Efron B . Pre-validation and inference in microarrays. Stat Appl Genet Mol Biol. 2006; 1:Article1. DOI: 10.2202/1544-6115.1000. View

Willenbrock H, Juncker A, Schmiegelow K, Knudsen S, Ryder L . Prediction of immunophenotype, treatment response, and relapse in childhood acute lymphoblastic leukemia using DNA microarrays. Leukemia. 2004; 18(7):1270-7. DOI: 10.1038/sj.leu.2403392. View

Ransohoff D . Rules of evidence for cancer molecular-marker discovery and validation. Nat Rev Cancer. 2004; 4(4):309-14. DOI: 10.1038/nrc1322. View

Michiels S, Koscielny S, Hill C . Prediction of cancer outcome with microarrays: a multiple random validation strategy. Lancet. 2005; 365(9458):488-92. DOI: 10.1016/S0140-6736(05)17866-0. View

Ramaswamy S, Perou C . DNA microarrays in breast cancer: the promise of personalised medicine. Lancet. 2003; 361(9369):1576-7. DOI: 10.1016/S0140-6736(03)13322-3. View

Beer D, Kardia S, Huang C, Giordano T, Levin A, Misek D . Gene-expression profiles predict survival of patients with lung adenocarcinoma. Nat Med. 2002; 8(8):816-24. DOI: 10.1038/nm733. View

Shipp M, Ross K, Tamayo P, Weng A, Kutok J, Aguiar R . Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning. Nat Med. 2002; 8(1):68-74. DOI: 10.1038/nm0102-68. View

10.

Cope L, Irizarry R, Jaffee H, Wu Z, Speed T . A benchmark for Affymetrix GeneChip expression measures. Bioinformatics. 2004; 20(3):323-31. DOI: 10.1093/bioinformatics/btg410. View

11.

Simon R . Roadmap for developing and validating therapeutically relevant genomic classifiers. J Clin Oncol. 2005; 23(29):7332-41. DOI: 10.1200/JCO.2005.02.8712. View

12.

Whitfield M, George L, Grant G, Perou C . Common markers of proliferation. Nat Rev Cancer. 2006; 6(2):99-106. DOI: 10.1038/nrc1802. View

13.

Huber W, von Heydebreck A, Sultmann H, Poustka A, Vingron M . Variance stabilization applied to microarray data calibration and to the quantification of differential expression. Bioinformatics. 2002; 18 Suppl 1:S96-104. DOI: 10.1093/bioinformatics/18.suppl_1.s96. View

14.

Ross M, Zhou X, Song G, Shurtleff S, Girtman K, Williams W . Classification of pediatric acute lymphoblastic leukemia by gene expression profiling. Blood. 2003; 102(8):2951-9. DOI: 10.1182/blood-2003-01-0338. View

15.

Bild A, Yao G, Chang J, Wang Q, Potti A, Chasse D . Oncogenic pathway signatures in human cancers as a guide to targeted therapies. Nature. 2005; 439(7074):353-7. DOI: 10.1038/nature04296. View

16.

Wessels L, Reinders M, Hart A, Veenman C, Dai H, He Y . A protocol for building and evaluating predictors of disease state based on microarray data. Bioinformatics. 2005; 21(19):3755-62. DOI: 10.1093/bioinformatics/bti429. View

17.

Irizarry R, Hobbs B, Collin F, Beazer-Barclay Y, Antonellis K, Scherf U . Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics. 2003; 4(2):249-64. DOI: 10.1093/biostatistics/4.2.249. View

18.

Tibshirani R . Immune signatures in follicular lymphoma. N Engl J Med. 2005; 352(14):1496-7. DOI: 10.1056/NEJM200504073521422. View

19.

Pomeroy S, Tamayo P, Gaasenbeek M, Sturla L, Angelo M, McLaughlin M . Prediction of central nervous system embryonal tumour outcome based on gene expression. Nature. 2002; 415(6870):436-42. DOI: 10.1038/415436a. View

20.

Ntzani E, Ioannidis J . Predictive ability of DNA microarrays for cancer outcomes and correlates: an empirical assessment. Lancet. 2003; 362(9394):1439-44. DOI: 10.1016/S0140-6736(03)14686-7. View